"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Learn more about Wegovy for weight loss. Ozempic, also semaglutide ... Some people who may not be able to receive Ozempic include: Zepbound works by activating the GLP-1 and glucose-dependent ...